Credit: AstraZeneca. Airsupra combines albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. Airsupra ® (albuterol/budesonide) is now available for the as-needed ...

Young woman using asthma inhaler at home. The NDA submission is supported by data from the phase 3 MANDALA trial, which included 3132 patients with moderate to severe asthma. The Food and Drug ...

For many children, asthma can be a constant specter, with attacks at the most inconvenient and terrifying times. New research has now found that one inhaler containing two drugs can cut the risk of ...

San Diego, Calif. – May 24, 2005 – Young children who are adherent with asthma controller therapies overall, and specifically PULMICORT RESPULES® (budesonide inhalation suspension), have lower ...

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...

Two drugs are better than one when it comes to stopping asthma attacks in progress, a new clinical trial has found. The study, of more than 3,100 asthma patients, found that a two-drug "rescue" ...

Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.

As asthma symptoms worsen, patients typically rely on short-acting β 2-agonist (SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves patients at risk for severe asthma ...

Please provide your email address to receive an email when new articles are posted on . A fixed-dose combination of albuterol and budesonide at 180/160 µg and 180/80 µg demonstrated significant ...